In Brief: Abbott/SpectRx
This article was originally published in The Gray Sheet
Abbott/SpectRx: Diagnostic firms are conducting "developmental studies" of a non-invasive monitor to measure glucose in interstitial fluid. The Jan. 19 "Gray Sheet" reported that pivotal trials for the device would commence in 1998. SpectRx still expects Abbott to submit a 510(k) for the device sometime in 1999, the company says...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.